- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07670897
Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
A Randomized, Open-label, Single-dose Study to Evaluate the Bioequivalence of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Yunda Zhuge
- Telefonnummer: 010-56456739
- E-mail: zhugeyunda@ganlee.com
Undersøgelse Kontakt Backup
- Navn: Shiyun Lai
- Telefonnummer: 010-56456739
- E-mail: shiyun.lai@ganlee.com
Studiesteder
-
-
Shandong
-
Linyi, Shandong, Kina, 276000
- Gan & Lee Pharmaceuticals Shandong Co., Ltd.,
-
Kontakt:
- Yunda Zhuge
- Telefonnummer: 010-56456739
- E-mail: zhugeyunda@ganlee.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
1. Voluntarily sign the Informed Consent Form (ICF), be willing to accept subcutaneous injection, fully understand the study content, procedures and potential adverse reactions, and be able to comply with the contraindications and restrictions specified in this protocol.
2. Male, aged 18 to 50 years (inclusive) at the time of ICF signing. 3. Body weight ≥ 50 kg and body mass index (BMI) within the range of 18.5 to 24.0 kg/m² (inclusive) at screening.
4. Male participants of childbearing potential have no plans for conception, voluntarily adopt effective contraceptive measures, and have no sperm donation plans from the date of ICF signing until 4 weeks after dosing.
Exclusion Criteria:
1. Have an allergic constitution, or a history of allergic diseases such as bronchial asthma and eczema (except for mild seasonal allergy); or have a history of severe food allergy (e.g., laryngeal edema, shock); or known allergy, hypersensitivity or intolerance to the investigational medicinal product (IMP) or similar products or their excipients; or have a clinically significant history of drug allergy or atopic allergic diseases.
2. Findings from physical examination, vital signs, routine laboratory tests, 12-lead electrocardiogram (ECG), chest imaging and other assessments at screening are judged to be clinically significant by the investigator.
3. Have special dietary requirements and are unable to comply with the standardized diet.
4. Have a history of needle phobia or blood phobia, have difficulty in blood collection, or cannot tolerate venous puncture for blood sampling.
5. The participant is an employee of the investigator or the study center, or a family member of an employee or the investigator; or the participant has other factors that, in the investigator's opinion, make him/her unsuitable for participation in the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: GZR4 injection A
|
GZR4 s.c., single-dose
|
|
Eksperimentel: GZR4 injection B
|
GZR4 s.c., single-dose
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cmax
Tidsramme: Day1-Day29
|
Peak concentration following single administration of GZR4
|
Day1-Day29
|
|
AUC₀-t
Tidsramme: Day1-Day29
|
Area under the plasma concentration-time curve from time zero to the last quantifiable sampling time point t after single administration of GZR4
|
Day1-Day29
|
|
AUC₀-∞
Tidsramme: Day1-Day29
|
Area under the plasma concentration-time curve from time zero to infinity after single administration of GZR4
|
Day1-Day29
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tmax
Tidsramme: Dag 1-Dag 29
|
Dag 1-Dag 29
|
|
t1/2
Tidsramme: Day1-Day29
|
Day1-Day29
|
|
AUC_%Extrap
Tidsramme: Day1-Day29
|
Day1-Day29
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- GZR4-T2D-106
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med T2D
-
Gan & Lee Pharmaceuticals.Rekruttering
-
Virginia Polytechnic Institute and State UniversityIkke rekrutterer endnuBlodtryk | Kardiometabolisk sundhed | T2DForenede Stater
-
Peking University Third HospitalIkke rekrutterer endnu
-
University of CopenhagenNovo Nordisk A/S; Steno Diabetes Center CopenhagenAfsluttet
-
Harvard School of Public Health (HSPH)Afsluttet
-
Nantes University HospitalUniversity Hospital, AngersAfsluttet
-
Wake Forest University Health SciencesRekrutteringType 2 diabetes mellitus (T2D)Forenede Stater
-
Eli Lilly and CompanyAfsluttetType 2 diabetes | T2DForenede Stater, Mexico, Argentina, Puerto Rico
-
SanofiRekrutteringType 2-diabetes (T2D)Kina
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetT2D | IGT - Nedsat glukosetoleranceForenede Stater
Kliniske forsøg med GZR4 injection A
-
Gan & Lee Pharmaceuticals.Aktiv, ikke rekrutterende
-
Gan and Lee Pharmaceuticals, USAAfsluttet
-
Gan and Lee Pharmaceuticals, USARekruttering
-
Gan & Lee Pharmaceuticals.Rekruttering
-
Gan and Lee Pharmaceuticals, USAAfsluttet
-
GE HealthcareRekrutteringOnkologi | Ondartet fast tumorHolland
-
Gan & Lee Pharmaceuticals.Ikke rekrutterer endnu
-
Gan and Lee Pharmaceuticals, USAProfil Institut für Stoffwechselforschung GmbHRekruttering
-
Jiangsu HengRui Medicine Co., Ltd.Ikke rekrutterer endnu
-
HugelAfsluttetBenign masseterisk hypertrofiKorea, Republikken